Tarsus Pharmaceuticals (TARS) Other Non-Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (changed N/A YoY), while the FY2025 annual figure was $10.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities was $16.1 million for Q1 2026 at Tarsus Pharmaceuticals, up from $10.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $16.1 million in Q1 2026 to a low of $40000.0 in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $3.4 million across 5 years, with a median of $1.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities tumbled 91.94% in 2023, then surged 3915.0% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $100000.0 in 2022, then soared by 1648.0% to $1.7 million in 2023, then declined by 29.06% to $1.2 million in 2024, then jumped by 754.76% to $10.6 million in 2025, then surged by 51.7% to $16.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $16.1 million (Q1 2026), $10.6 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.